drugset
drugset / Trial / NCT01871311

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

NCT01871311 ↗

Phase 1 Terminated 15 enrolled Georgetown University Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the recommended Phase II dose of nilotinib when used in combination with cetuximab in the treatment of patients with recurrent and/or metastatic Kras wildtype colorectal cancer or squamous cell carcinoma of the head and neck.

Timeline

Start
2014-05
Primary completion
2016-12
Completion
2016-12

Outcome

Outcome not reported

Stopped: “Primary investigator left the institution.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 250 mg/m2 —
Subject Nilotinib Small molecule 200 mg —
Subject Nilotinib Small molecule 300 mg —

Indications

colorectal cancer head and neck squamous cell carcinoma